Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4

Clinical Kidney Journal

Volumn 7, Issue 2, 2014, Pages 167-173

  Weber, Chek Ing Kiu ^a   Duchateau Nguyen, Guillemette ^a   Solier, Corinne ^a   Schell Steven, Annette ^a   Hermosilla, Ricardo ^a   Nogoceke, Everson ^a   Block, Geoffrey ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Denver Nephrology   (United States)

Author keywords

arterial calcification; biomarkers; cardiovascular risk; chronic kidney disease; inflammation

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CYSTATIN C; EDETIC ACID; EOTAXIN 2; FIBROBLAST GROWTH FACTOR 23; GELATINASE A; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; LATENCY ASSOCIATED PEPTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHORUS; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ABDOMINAL AORTA CALCIFICATION; AGED; ARTERY CALCIFICATION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ELECTRON BEAM TOMOGRAPHY; FEMALE; GLOMERULUS FILTRATION; HISTOCOMPATIBILITY COMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA CALCIFICATION;

EID: 84897468981     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu017     Document Type: Article

References (37)

1. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28
2. Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 4: other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl 2013; 3: 91-111
3. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
4. Van der Zee S, Baber U, Elmariah S et al. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009; 6: 580-589
5. KoenigW. Recent developments in cardiovascular risk assessment: relevance to the nephrologist. Nephrol Dial Transplant 2011; 26: 3080-3083
6. Weiner DE, Tighiouart H, Elsayed EF et al. The framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50: 217-224 (Pubitemid 47031564)
7. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 672-681
8. Shankar A, Sun L, Klein BEK et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 2011; 80: 1231-1238
9. Budoff MJ, Shaw LJ, Liu ST et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49: 1860-1870 (Pubitemid 46661110)
10. Polonsky TS, McClelland RL, Jorgensen NW et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303: 1610-1616
11. Blaha MJ, Budoff MJ, DeFilippis AP et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011; 378: 684-692
12. Yeboah J, McClelland RL, Polonsky TS et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals risk markers in cardiovascular risk assessment. JAMA 2012; 308: 788-795
13. Kavousi M, Elias-Smale S, Rutten JH et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Int Med 2012; 156: 438-444
14. Budoff MJ, Rader DJ, Reilly MP et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2011; 58: 519-526
15. Cao X-F, Yan L-Q, Han L-X et al. Association of mild to moderate kidney dysfunction with coronary artery calcification in patients with suspected coronary artery disease. Cardiology 2011; 120: 211-216
16. Russo D, Corrao S, Battaglia Y et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 2011; 80: 112-118
17. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
18. Spiegel DM, Raggi P, Mehta R et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004; 8: 265-272 (Pubitemid 41024997)
19. Callister TQ, Raggi P, Cooil B et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972-1978 (Pubitemid 29024129)
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Version 2. 11. 1. Vienna, Austria: 2010. http://www. lsw. uni-heidelberg. de/users/christlieb/ teaching/UKStaSS10/R-refman. pdf (25 September 2013, date last accessed)
21. Allison MA, Hsi S, Wassel CL et al. Calcified atherosclerosis in different vascular beds and the risk of mortality. Artherioscler Thromb Vasc Biol 2012; 32: 140-146
22. ACCF/AHA. ACCF/AHA 2007 Clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation 2007; 115: 402-426
23. Vraetz T, Ittel TH, van Mackelenbergh MG et al. Regulation of beta2-microglobulin expression in different human cell lines by proinflammatory cytokines. Nephrol Dial Transplant 1999; 14: 2137-2143 (Pubitemid 29403402)
24. Wilson AM, Kimura E, Harada RK et al. 2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007; 116: 1396-1403 (Pubitemid 47417566)
25. Amighi J, Hoke M, Mlekusch Wet al. Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2011; 42: 1826-1833
26. Liabeuf S, Lenglet A, Desjardins L et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012; 82: 1297-1303
27. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
28. Roos M, Lutz J, Salmhofer H et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008; 68: 660-665 (Pubitemid 351388700)
29. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276
30. Schoppet M, Hofbauer LC, Brinskelle-Schmal N et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO Study. J Clin Endocrinol Metab 2012; 97: E575-E583
31. Jean G, Bresson E, Terrat J-C et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2008; 24: 948-955
32. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513 (Pubitemid 44387485)
33. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
34. Nakayama M, Kaizu Y, Nagata M et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol 2013; 14: 22
35. Yong K, Ooi EM, Dogra G et al. Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness. Cytokine 2013; 64: 39-42
36. Honda H, Qureshi AR, Heimbürger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148 (Pubitemid 41828276)
37. Hamirani YS, Pandey S, Rivera JJ et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 2008; 201: 1-7